Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT04385368 · COMPLETED
Trial details
- NCT number
- NCT04385368
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-17
- Primary completion
- 2023-08-31
- Enrollment
- 89
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.